

Original Article

The effect of low-level estrogen in mandibular bone: An *in vivo* study

Nike Hendrijanti¹, Rostiny Rostiny¹, Mefina Kuntjoro¹, Hanoem Eka Hidajati¹, Soekobagiono Soekobagiono¹,
Adi Subianto¹, Maretaningtias Dwi Ariani¹, Dika Agung Bakhtiar¹

¹Department of Prosthodontics, Faculty of Dental Medicine, Universitas Airlangga, Mayjen, Surabaya, Indonesia

ABSTRACT

Background: Low levels of estrogen can cause osteoporosis and usually occur during a woman's menopausal phase. Osteoporosis can lead to bone resorption, the absence of osseointegration, and implant failure. The aim of this study is to determine the expression of transforming growth factor-beta 1 (TGF- β 1), runt-related transcription factor (RUNX2), and osteoblasts in mandibular rats with low levels of estrogen.

Materials and Methods: This study is an *in vivo* experimental research. Female Wistar rats ($n = 18$) were divided into two groups: (1) Postsham surgery and (2) ovariectomy group. After 12 weeks, the rats were sacrificed to identify the level of estrogen, while histological analysis was conducted to determine the level of osteoblast and the expression of TGF- β 1 and RUNX2. The data were analyzed using *t*-test ($P < 0.05$).

Results: There were significant lower levels of estrogen and osteoblast among the ovariectomy group compared to the postsham group ($P < 0.05$). RUNX2 levels were found to be significantly higher in the ovariectomy group than that in the postsham group ($P < 0.05$). However, there were no significant differences between TGF- β 1 levels within the ovariectomy and postsham groups ($P > 0.05$).

Conclusion: Ovariectomy can lead to decreased osteoblastogenesis in mandibular bone by the reduced level of osteoblast and the increased expression of TGF- β 1 and RUNX2.

Key Words: Estrogens, osteoblasts, osteoporosis

Received: July 2017
Accepted: October 2017

Address for correspondence:
Dr. Nike Hendrijantini,
Mayjen Prof. Dr. Moestopo
47, Surabaya - 60132,
Indonesia.
E-mail: nike-h@fkg.unair.ac.id

INTRODUCTION

Every year in Indonesia, the number of elderly people above 60 years old increases.^[1] Within the health sector, elderly patients are particularly vulnerable due to the degenerative process related to aging. In this condition, many elderly people need prosthodontic treatment. One of the common degenerative diseases is osteoporosis, especially in postmenopausal women.^[2,3] The decrease in bone mass of 2%–5% per year is related to reduced calcium uptake due to a

decrease in the level of estrogen which is crucial for bone growth and repair. The reduced bone mass may, in turn, increase the risk of osteoporosis.^[4]

Osteoporosis can negatively impact the condition of teeth and oral cavities. Indeed, tooth loss is one complication of osteoporosis affecting the oral cavity.^[5] Osteoporosis not only occurs in lumbar, femoral, and radial bones, but also in the jaw bone, therefore demanding the attention of dentists.^[4,6] Osteoporosis

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Hendrijanti N, Rostiny R, Kuntjoro M, Hidajati HE, Soekobagiono S, Subianto A, *et al.* The effect of low-level estrogen in mandibular bone: An *in vivo* study. *Dent Res J* 2019;16:65-70.

Access this article online	
	Website: www.drj.ir www.drjournal.net www.ncbi.nlm.nih.gov/pmc/journals/1480

also causes resorption of alveolar bone and reduced mandibular cortex thickness which increase the risk of periodontal disease and tooth loss.^[7] Mandibular bone remodeling failure causes alveolar bone loss in surrounding teeth which increases the risk of tooth mobility culminating in tooth loss.^[8]

Prosthodontists require an unqualified evaluation of bone density to decide on the appropriate treatment for patients. Menopausal women with osteoporosis require special attention during implant treatment, especially at the implant insertion stage. Osteoporotic women suffer from a low level of estrogen resulting in their bone density decreasing by 50% in trabecular bone and 35% in cortical bone.^[9,10] Estrogen executes an important role in bone formation. Its deficiency can lead to imbalance in remodeling process due to a reduced ratio of osteoblast to osteoclast. Osteoblastogenesis disruption can cause decreases in bone density, the extent of which can be determined by bone mineral density examination.^[11,12]

One treatment option within prosthodontics is dental implant which is a new and effective remedy for tooth replacement.^[13] Dental implants require appropriate bone density due to the latter's relationship with the mechanical immobilization of such implants during the healing process.^[14] Bone density plays an important role within the equal distribution and transmission of denture load on the implants within the bone.^[15] Osteointegration between implant and bone is a key to the success of implant treatment. The study showed that implant failure might occur due to low bone density which leads to incomplete osseointegration of the implant and bone.^[13] Therefore, for women suffering from osteoporosis who require implant treatment, early detection of the condition is a prerequisite to the prevention of dental implant failure.

Estrogen is a hormone that maintains the equilibrium between osteoblast and osteoclast activities.^[16] Decreasing estrogen levels in menopausal women will lead to reduced bone morphogenic protein 2 (BMP2) which constitutes an osteogenic regulator. Lower BMP2 levels lead to decreased runt-related transcription factor (RUNX2) levels which are a major transcription factor of direct osteoprogenitors and ensure osteogenic differentiation.^[17] BMP2 is a family member of transforming growth factor-beta 1 (TGF- β 1) protein which has an important function in osteogenesis. Osteoporosis is also related to a

decreasing number of osteoblast progenitors in bone marrow and defects in mesenchymal stem cells (MSCs). This condition decreases bone density through a reduction in the proliferation and differentiation process of osteoblasts.^[16,18]

Nowadays, effective diagnosis of osteoporosis still relies on X-ray examination to determine the bone mineral density.^[19-21] The last study demonstrated that X-ray examinations do not provide an adequate result to diagnose osteoporosis.^[21] The detailed condition of mandibular osteoporosis has yet to be studied. Research on the state of the mandibular bone cannot be conducted on humans. Therefore, the study reported here involved the use of animal osteoporotic model. It is hypothesized that osteoporotic bone also found in mandibula in low level of estrogen and can affect the osteoblastogenesis. A definitive diagnosis of an osteoporotic mandible is necessary for successful prosthodontic treatment. The aim of this study is to determine the expression of TGF- β 1, RUNX2, and osteoblast in mandibular rats with low levels of estrogen.

MATERIALS AND METHODS

Animal preparation

This research constituted an *in vivo* experiment incorporating the use of posttest group design and had been granted ethical approval clearance by the Committee of Ethical Clearance of Health Research, Faculty of Dental Medicine, Universitas Airlangga No. 14/KKEPK. FKG/I/2016. Sample size was calculated using Lemeshow formula.^[22] The sample consisted of 18, 3-month old, female *Rattus norvegicus* strain Wistar rats weighing 180–200 g which were kept in cages for a week before ovariectomy and sham surgery was carried out. The rats had fasted for 6–8 h before surgery. Ketamine 10% 1 cc and Xyla 1 cc were injected intramuscularly into the semi-tendinous muscle and valium 0.2 mg/kg in gluteus was administered as an anesthetic. An ovariectomy was performed through ventral and umbilical incision as far as the pubic region. Ovarium and fallopian blood vessels were ligated separately, while the bilateral ovaries and periovarian fat were removed entirely. The peritoneal incision was closed by means of a simple suture prior to skin closure. The sham surgery group alone underwent peritoneal incision without the removal of the ovarium before being closed with a simple suture and skin closure. The rats were released

postoperatively within the cage on a normal diet for 12 weeks.

Estrogen-level examination

Three ml blood samples for estrogen examination were taken directly from the apex of the heart using a 5 ml disposable syringe after the rats had been anesthetized. An ELISA Kit (Sigma-Aldrich, St. Louis, MO) was used for estrogen-level examination.

Histological and immunohistochemistry analysis

At 12 weeks postintervention, the rats were euthanized and the mandibular bone was taken for microscopic examination. Immunohistochemistry (IHC) analysis was conducted using the monoclonal antibody for TGF- β 1 (Sigma-Aldrich, St. Louis, MO), while RUNX2 (Sigma-Aldrich, St. Louis, MO) detection and histological examination were conducted using Meyer's hematoxylin staining (Sigma-Aldrich, St. Louis, MO).

Statistical analysis

The percentage of estrogen level, osteoblast, TGF- β 1 and RUNX2 marker-positive cells are depicted as the mean value \pm standard deviation. Statistical significant was conducted using *t*-test, $P < 0.05$ being considered a significant result.

RESULTS

This research was performed using 18 Wistar rats as postsham surgery with a control group and ovariectomy surgery with an interventional group. Immunohistochemical and histopathological preparations of a mandibular bone sample in the molar region were made, with the expression of TGF- β 1, RUNX2, and osteoblast number on the control, postsham, and ovariectomy groups being analyzed using a light microscope.

Microscopic evaluation using IHC revealed an expression of TGF- β 1 and RUNX2 as shown in Figures 1 and 2. Microscopic evaluation using histopathology revealed an osteoblast [Figure 3]. The black arrow indicates an expression of TGF- β 1, RUNX2, and osteoblast under microscopic examination.

The results of this study, illustrated as mean values of estrogen, TGF- β 1, RUNX2, and osteoblast level for each group, are presented in Table 1. There were higher levels of estrogen and osteoblast in the postsham surgery group than its ovariectomy counterpart. However, lower levels of TGF- β 1 and




Figure 1: Immunohistochemistry staining from SHS and OVX for TGF- β 1 expression. Black arrow shows an expression of TGF- β 1. SHS: Postsham surgery group; OVX: Postovariectomy group; TGF- β 1: Transforming growth factor-beta 1 \times 400.




Figure 2: Immunohistochemistry staining from SHS and OVX for RUNX2 expression. Black arrow shows an expression of RUNX2. SHS: Postsham surgery group; OVX: Postovariectomy group; RUNX2: Runt-related transcription factor \times 400.




Figure 3: Histopathology examination from SHS and OVX for osteoblast level. Black arrow shows an osteoblast. SHS: Postsham surgery group; OVX: Postovariectomy group \times 400.

RUNX2 were revealed in the postsham surgery group than the ovariectomy group. According to statistical analysis, there was a significant difference in estrogen, RUNX2, and osteoblast level between the two groups ($P < 0.05$). Meanwhile, there was no significant difference in TGF- β 1 between the two groups ($P > 0.05$).

DISCUSSION

This study was conducted using the *R. norvegicus* strain of Wistar rats as an animal subject. These rodents are commonly used as a clinical experiment subject due to their rapid regeneration and ease of maintenance. Rats represent the best subjects for osteoporosis research due to the similarity of their

Table 1: Mean, standard deviation, and significance value (P) of every group for estrogen, transforming growth factor-beta 1, runt-related transcription factor 2 and osteoblast level (ng/ml)

Variable	Group	Mean±SD	P
Estrogen level	SHS	92.3889±21.16379	0.001*
	OVX	59.0111±14.10367	
TGF-β1 level	SHS	3.7778±2.42991	0.927
	OVX	3.8667±1.50333	
RUNX2 level	SHS	0.7778±0.29059	0.000*
	OVX	4.6000±1.63401	
Osteoblast level	SHS	392.6667±84.77323	0.000*
	OVX	213.0000±40.85034	

*P<0.05 was considered as a significant difference for each group. SHS: Postsham surgery group; OVX: Postovariectomy group; TGF-β1: Transforming growth factor-beta 1; RUNX2: Runt-related transcription factor 2; SD: Standard deviation

trabecular bone and bone regeneration ability with that of postmenopausal women.^[23]

Estrogen deficiencies in osteoporosis induce bone resorption, resulting in changes to bone microarchitecture. Bone formation disruption can occur in postmenopausal women due to estrogen deficiencies. In osteoporosis, bone formation potential will be limited as shown by the decreased capacity of osteoblasts to form a bone matrix.^[17] Histological analysis confirmed osteoporosis to be determined by a decrease in trabecular bone, while a severe osteoporosis condition leads to thin trabecular bones and causes functional insufficiency.^[24] In this study, there was no significant difference between TGF-β1 expression in the normal individuals and osteoporotic patients. This result can be produced by the varying role of TGF-β1 at each stage of bone formation. TGF-β1 stimulates RUNX2 at the differentiation stage of osteoblastogenesis and inhibits the continuing phase after osteoblast maturation. RUNX2, as an important transcription factor in bone formation, is regulated by TGF-β1 and BMP2. TGF-β1 induces the expression of RUNX2, thereby potentially increasing a differentiation, but at an advanced phase, TGF-β1 will inhibit the expression of RUNX2 to prevent mature osteoblast differentiation into osteocytes.^[25]

There was an increase in TGF-β1 expression at an early stage of injury response. TGF-β1 is produced at the fracture site by platelets, inflammatory cells (monocytes and macrophages), osteoblasts, osteoclasts, and chondrocytes.^[26] In this study, TGF-β1 was expressed at the end of the 12th week after the ovariectomy had been performed, whereas other studies have shown that TGF-β1 expression presented at an early stage in the injury response.^[27,28]

Therefore, there is no significant difference between TGF-β1 expression in the normal and osteoporosis groups.

TGF-β1 is the largest bone growth factor and the most prominent among the three forms of TGF-β. TGF-β1 produced osteoblasts as inactive propeptides which are incorporated into the bone matrix. During resorption, an inactive propeptide will be activated at the resorption site. TGF-β1 inhibits osteoclast activity and stimulates preosteoblast proliferation and differentiation to support bone formation.^[29] TGF-β1 will be mobilized by osteoclasts and attract MSC to the site to promote osteoblast differentiation.^[30]

In this study, there was a significant difference between the RUNX2 expression in an ovariectomy group and that of a normal group. RUNX2 enhancement means that bone remodeling still occurs at the 12-week postovariectomy, although some osteoblasts may have matured into osteoids. MSC differentiation into osteoblast occurs in several phases with each phase is being characterized by a particular osteoblast marker gene. RUNX2 regulates the expression of the osteoblast marker gene in conjunction with osteocalcin-specific element 2 (OSE2), a binding site for RUNX2. OSE2 was found in the promoter region of all major osteoblast marker genes. RUNX2 has several isoforms, which have their own roles and functions at each stage of osteoblast differentiation. RUNX2 type 1 in mice, that have two main isoforms, has been found in osteoprogenitor and preosteoblasts cells, indicating that it has an important role in the early stages of osteoblastogenesis, while in the final stage, RUNX2 type 2 induces osteoblast maturation. It has been shown that at week 12, osteoblastic differentiation remains ongoing in the osteoporosis group.^[31]

RUNX2 is important for osteoblast differentiation and bone formation, being a transcription factor of DNA-specific binding that regulates and controls the development of osteoblasts from MSCs and maturation into osteocytes. Although necessary for transcriptional gene and osteoblast development, RUNX2 is an inadequate optimal expression gene for bone formation. In accordance with its function as a master organizer, changes in the RUNX2 expression level will be related to skeletal bone disease.^[32]

TGF-β1 as a growth factor plays an important role in the proliferation of preosteoblasts and their differentiation into osteoblasts. Moreover, RUNX2

acts as a transcriptional gene affecting osteoblast formation. Increased TGF- β 1 leads to the stimulation of RUNX2 in the osteoblast proliferation and differentiation phases. Both will subsequently decrease in the maturation phase.^[33] Estrogen deficiency condition in osteoporosis leads to bone remodeling enhancement with increased bone resorption over bone formation. This condition involves unbalanced osteoblast and osteoclast activity and leads to bone microarchitecture changes that reduce bone density.^[11,34]

A decrease in bone density is an early sign of osteoporosis. One method of determining such a decline is to perform osteoblast and osteoclast examinations.^[34] The results of this study indicate a significantly smaller number of osteoblasts in the osteoporosis group compared to the normal group, which is associated with decreased estrogen level. The lower levels of estrogen lead to the suppression of MSC production and the number of preosteoblasts. And that of osteoblasts will also decrease.

The mineralization process begins 30 days after osteoid deposition and terminates on the 90th day within the trabecular bone. It also occurs on the 130th day within the cortical bone.^[35] Hence, by the 12th week after the ovariectomy has been performed, mineralization of the trabecular bone occurs.

CONCLUSION

From the results of this study, it can be concluded that the condition of low estrogen levels can lead to decreased osteoblastogenesis in the mandibular bone, characterized by increased expression of TGF- β 1 and RUNX2 and a decline in the number of osteoblasts.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors of this manuscript declare that they have no conflicts of interest, real or perceived, financial or nonfinancial, in this article.

REFERENCES

1. Pramono T. Badan Pusat Statistika. Statistik Penduduk Lanjut Usia; 2014, c2015. Available from: <https://www.bps.go.id/index.php/publikasi/1117>. [Last accessed on 2017 Aug 15].
2. Partida MN. Geriatric prosthodontic care. *Dent Clin North Am* 2014;58:103-12.
3. Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL. Management of age-related osteoporosis and prevention of associated fractures. *Ther Clin Risk Manag* 2006;2:281-95.
4. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Cunningham FG. Reproductive endocrinology, infertility, and the menopause. In: Williams Gynecology. 3rd ed. New York: McGraw-Hill Education; 2016. p. 471-90.
5. Nicopoulou-Karayianni K, Tzoutzoukos P, Mitsea A, Karayiannis A, Tsiklakis K, Jacobs R, *et al.* Tooth loss and osteoporosis: The OSTEODENT study. *J Clin Periodontol* 2009;36:190-7.
6. Speroff L, Fritz M. Menopause and the perimenopausal transition. In: Clinical Gynecologic Endocrinology and Infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 673-747.
7. Kafadar IH, Güney A, Türk CY, Oner M, Silici S. Royal jelly and bee pollen decrease bone loss due to osteoporosis in an oophorectomized rat model. *Eklem Hastalik Cerrahisi* 2012;23:100-5.
8. Nobuhara WK, Carnes DL, Gilles JA. Anti-inflammatory effects of dexamethasone on periapical tissues following endodontic overinstrumentation. *J Endod* 1993;19:501-7.
9. Keen R. Pathology of osteoporosis. In: Clunie G, Keen R, editor. Osteoporosis. 2nd ed. New York: Oxford University Press; 2014. p. 1-7.
10. Salim S. Correlation between estrogen and alkaline phosphatase expression in osteoporotic rat model. *Dent J* 2016;49:76-80. Available from: <http://www.e-journal.unair.ac.id/index.php/MKG/article/view/2995>. [Last accessed on 2017 Aug 10].
11. Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. *Nat Rev Endocrinol* 2013;9:699-712.
12. Marcu F, Bogdan F, Muțiu G, Lazăr L. The histopathological study of osteoporosis. *Rom J Morphol Embryol* 2011;52:321-5.
13. Misch CE. Rationale for dental implants. In: Contemporary Implant Dentistry. 3rd ed. St. Louis, Canada: Mosby Inc.; 2008. p. 3-21.
14. Saini R. Dental implant: A review. *J Dent Sci* 2013;1:8-11.
15. Bandela V, Munagapati B, Karnati RK, Venkata GR, Nidudhur SR. Osteoporosis: Its prosthodontic considerations – A review. *J Clin Diagn Res* 2015;9:ZE01-4.
16. Wang Z, Goh J, Das De S, Ge Z, Ouyang H, Chong JS, *et al.* Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. *Tissue Eng* 2006;12:1753-61.
17. Marie PJ, Kassem M. Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets. *Eur J Endocrinol* 2011;165:1-10.
18. Chen G, Deng C, Li YP. TGF- β and BMP signaling in osteoblast differentiation and bone formation. *Int J Biol Sci* 2012;8:272-88.
19. Kaye EK. Bone health and oral health. *J Am Dent Assoc* 2007;138:616-9.
20. Dervis E. Oral implications of osteoporosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2005;100:349-56.
21. Devlin H, Horner K. Mandibular radiomorphometric indices in the diagnosis of reduced skeletal bone mineral density. *Osteoporos Int* 2002;13:373-8.
22. Lemeshow S, Hosmer DW, Klar J, Lwango SK. Sample size for continuous response variable. In: Adequacy of Sample Size in Health Studies. Chichester, West Sussex: John Wiley & Sons Ltd.; 1990. p. 36-40.

Hendrijanti, *et al.*: Low-level estrogen in mandibular bone

23. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA guidelines and animal models for osteoporosis. *Bone* 1995;17:125S-133S.
24. Lestari S, Utari EL. Metode pengenalan pola trabekula mandibula pada radiograf periapikal digital untuk deteksi dini risiko osteoporosis. *Teknosains* 2013;3:66-73. Available from: <https://www.jurnal.ugm.ac.id/teknosains/article/view/6129>. [Last accessed on 2017 Aug 10].
25. Kasagi S, Chen W. TGF-beta1 on osteoimmunology and the bone component cells. *Cell Biosci* 2013;3:4.
26. Sfeir C, Ho L, Doll BA, Azari K, Hollinger JO. Fracture repair. In: Lieberman JR, Friedlaender GE, editors. *Bone Regeneration and Repair Biology and Clinical Application*. Totowa, New Jersey: Humana Press; 2005. p. 21-44.
27. Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, *et al.* Regulation of RANKL-induced osteoclastogenesis by TGF- β through molecular interaction between smad3 and traf6. *J Bone Miner Res* 2011;26:1447-56.
28. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. *J Cell Biochem* 2001;83:320-5.
29. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. *Bone* 2003;32:297-310.
30. Teitelbaum SL. Stem cells and osteoporosis therapy. *Cell Stem Cell* 2010;7:553-4.
31. Jeong JH, Choi JY. Interrelationship of runx2 and estrogen pathway in skeletal tissues. *BMB Rep* 2011;44:613-8.
32. Shui C, Spelsberg TC, Riggs BL, Khosla S. Changes in runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. *J Bone Miner Res* 2003;18:213-21.
33. Kini U, Nandeesh BN. Physiology of bone formation, remodeling, and metabolism. In: Fogelman I, Gnanasegaran G, Van der Wall H, editors. *Radionuclide and Hybrid Bone Imaging*. Berlin: Springer; 2012. p. 29-57.
34. Clarke B. Normal bone anatomy and physiology. *Clin J Am Soc Nephrol* 2008;3 Suppl 3:S131-9.
35. Pino AM, Rosen CJ, Rodríguez JP. In osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. *Biol Res* 2012;45:279-87.